Dissecting the Underlying Pharmaceutical Mechanism of Chinese Traditional Medicine Yun-Pi-Yi-Shen-Tong-Du-Tang Acting on Ankylosing Spondylitis through Systems Biology Approaches

Xie, Dizhi; Huang, Lin; Zhao, Guang‐Hui; Yu, Yiran; Gao, Jiawei; Li, Haichang; Wen, Chengping

doi:10.1038/s41598-017-13723-3

Cited by 7 publications

(5 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ankylosing spondylitis falls into the categories of “nephroparalysis” and “bone impediment” in traditional Chinese medicine (TCM) [ 8 – 10 ]. In the treatment of ankylosing spondylitis, Chinese medicine mainly focuses on replenishing the liver and kidneys, replenishing qi and blood, dispelling rheumatism, and relieving arthralgia [ 11 , 12 ]. The clinical application of TCM in the treatment of ankylosing spondylitis is based on a wealth of experience.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Duhuo Jisheng Decoction in Treating Ankylosing Spondylitis: Clinical Evidence and Potential Mechanisms

Wang

Zhou

Chen

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Duhuo Jisheng Decoction (DHJSD) is an ancient compound widely used in the treatment of ankylosing spondylitis (AS). However, its efficacy is controversial, and its mechanism of action is not clear enough. Using meta-analysis and network pharmacology, our study evaluated the clinical efficacy of DHJSD in the treatment of AS and explored its mechanisms of action. Methods. We searched medical databases, including Embase, PubMed, the China National Knowledge Infrastructure databases, Wanfang, and the Chinese Scientific Journal Database, to identify studies that met the inclusion criteria. RevMan 5.3 software was used for the meta-analysis. The compounds and the potential protein targets of DHJSD were obtained from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database and analysis platform. AS was treated as a search query in the NCBI, PharmGKB, TTD, DrugBank, and OMIM databases to obtain disease-related genes. The overlapping targets of DHJSD and AS were identified, and then Gene Ontology functional enrichment and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were performed. Cytoscape was employed to construct a drug-compound-target network and a protein-protein interaction (PPI) network. CytoHubba was utilized to select the hub genes. Results. A total of 10 studies involving 860 participants were included in the meta-analysis. Compared with the control, DHJSD treatment significantly improved clinical symptoms; reduced the erythrocyte sedimentation rate (ESR), the C-reactive protein (CPR), and interleukin 6 (IL-6) levels; increased the degree of motion of the chest; reduced the visual analog scale (VAS) pain score; reduced Schober’s test values; reduced the finger-to-floor distance; reduced the duration of morning stiffness. However, the differences were not statistically significant in the Bath Ankylosing Spondylitis Functional Index scores, the Bath Ankylosing Spondylitis Disease Activity Index scores, the bone Gla-containing protein (BGP) levels, or the bone alkaline phosphatase (BALP) levels. In terms of adverse events, DHJSD treatment of AS reduced the incidence of gastrointestinal events, the incidence of skin events, and the incidence of abnormal liver function; however, there was no statistically significant reduction in the incidence of adverse renal function events. Subgroup analysis showed that in the treatment of AS, the clinical effect of DHJSD for AS was better than that of the controls for both treatment durations, ≤2 months and >2 months. A total of 178 active compounds and 47 related potential targets were identified for DHJSD in the treatment of AS, including four hub genes (CXCL8, PTGS2, VEGFA, and STAT3). The core active ingredients of DHJSD in the treatment of AS were mainly quercetin, kaempferol, licochalcone A, and isorhamnetin. DHJSD treatment of AS-related pathways mainly involved the IL-17 signaling pathway, the TNF signaling pathway, and the rheumatoid arthritis signaling pathway. Conclusion. The above results suggest that DHJSD acts on AS through multiple targets, components, and pathways with significant clinical efficacy. Future studies may further explore the active components of DHJSD.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of Duhuo Jisheng Decoction in Treating Ankylosing Spondylitis: Clinical Evidence and Potential Mechanisms

Wang

Zhou

Chen

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Network pharmacology is an approach to predict disease-specific targets from biomedical data available in systems biology and polypharmacology [ 19 ]. With the development of biomedical data, new methods based on “active ingredient-target-disease” and interaction networks have been developed to understand the complex pharmacological mechanisms of Chinese medicine, and have blossomed in recent years [ 20 , 21 ]. Network pharmacology's fundamental principles and the holistic view of Chinese medicine are intertwined, leading to a change from the traditional “one target, one drug” paradigm to the more recent “multicomponent, multitarget” model, which is the most effective model for addressing multitarget medications [ 22 , 23 ].…”

Section: Introductionmentioning

confidence: 99%

Network Pharmacology and Molecular Docking Analysis Explores the Mechanisms of Cordyceps sinensis in the Treatment of Oral Lichen Planus

Wang

Guo

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Objective. Oral lichen planus (OLP) is the most common potentially malignant disorder of the oral cavity. This study aimed to investigate the mechanism of action of Cordyceps sinensis in the treatment of OLP and provides a theoretical support for improving current treatment regimens for OLP. Methods. The active components and therapeutic targets of Cordyceps sinensis were predicted and screened using the TCMSP, SymMap, PubMed, HIT 2.0, and PharmMapper databases, while the relevant OLP targets were predicted and screened using the DisGeNET and GeneCards databases. Protein-protein interactions (PPI) were examined using the String database, and Cytoscape was used to combine and illustrate the findings. GO and KEGG pathway enrichment analyses were carried out using RStudio, and AutoDock Vina and Pymol were used for molecular docking and visualization, respectively. Results. A total of 404 potential target genes were discovered after evaluating 21 active compounds from Cordyceps sinensis. Potential therapeutic targets included 67 targets that matched and overlapped with OLP, including TNF, IL-6, CD4, EGFR, and IL1B. Key targets were predominantly engaged in the PI3K-Akt signaling pathway and the MAPK signaling pathway, according to the GO and KEGG analyses. These targets have a connection to biological processes including apoptosis signaling pathway regulation, T cell activation, and oxidative stress response. The molecular docking results showed that TNF, IL-6, CD4, EGFR, and IL1B could bind to their corresponding active components. Conclusions. Cordyceps sinensis contains multiple components and acts on multiple targets and multiple pathways. Particularly, Cordyceps sinensis targets TNF, IL-6, CD4, EGFR, and IL1B, regulates PI3K-Akt and MAPK signaling pathways, as well as takes part in biological processes including apoptosis, T cell activation, and oxidative stress. Cordyceps sinensis could be a crucial choice in the therapy of OLP.

show abstract

“…The study of AS in Traditional Chinese Medicine (TCM) has a long history and has accumulated extensive experience in treating AS, and some Chinese herbal formulas (CHF) have been confirmed to have better clinical effects on this disease [22] . On the basis of the holistic concept and syndrome differentiation, TCM can be directed at different pathogenic links, using a variety of methods, and through multiple pathways, to achieve the effect of treating diseases and regulating immunity, and can alleviate the side effects of western medicine [23] . Therefore, integrated TCM and western medicine in the treatment of AS can synergize with each other to exert their own advantages, which can both remove multiple pathogenic factors of AS and improve the systemic status to achieve the best therapeutic effect [24] .…”

Section: Introductionmentioning

confidence: 99%

“…[22] On the basis of the holistic concept and syndrome differentiation, TCM can be directed at different pathogenic links, using a variety of methods, and through multiple pathways, to achieve the effect of treating diseases and regulating immunity, and can alleviate the side effects of western medicine. [23] Therefore, integrated TCM and western medicine in the treatment of AS can synergize with each other to exert their own advantages, which can both remove multiple pathogenic factors of AS and improve the systemic status to achieve the best therapeutic effect. [24] At present, a host of clinical trials have shown that CHF combined with western medicine has good clinical effectiveness and safety in the treatment of AS.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness and safety of Chinese herbal formula combined with western medicine for ankylosing spondylitis

Miao¹,

Deng²,

2021

Medicine

View full text Add to dashboard Cite

Background: Ankylosing spondylitis (AS) is a chronic progressive inflammatory disease of the spine, which mainly invades the sacroiliac joint, spine, and large joints near the trunk, leading to fibrous and skeletal ankylosis and deformity, and can cause damage to the eyes, lung, cardiovascular, kidney and other organs. Chinese herbal formulas (CHF) is an important interventions of Traditional Chinese Medicine (TCM), and CHFs combined with western medicine are widely used in clinical practice to treat AS. Methods: Eight databases will be systematically retrieved from their inceptions to March 2021. Only randomized controlled trials (RCTs) of CHFs combined with western medicine for AS treatment will meet the inclusion criteria. The primary outcomes we focus on include clinical effectiveness rate, TCM syndrome score, TCM symptom score, Bath ankylosing spondylitis disease activity index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), chest expansion, nocturnal spinal pain, adverse reactions, erythrocyte sedimentation rate (ESR), and C protein response (CRP). The research screening, data extraction, and risk of bias assessment will be performed independently by 2 researchers, and divergence will be solved by a third researcher. Revman 5.3 software will be used for meta-analysis. The confidence of evidence will be graded using grading of recommendations assessment, development, and evaluation (GRADE) algorithm and methodological quality will be assessed adopting risk of bias in systematic reviews (ROBIS). Results: This systematic review (SR) will provide evidence-based medical evidence for AS therapy by CHF combined with western medicine and we will submit the findings of this SR for peer-review publication. Conclusions: This SR will provide latest and updated summary proof for assessing the effectiveness and safety of CHF combined with western medicine for AS. Registration number: INPLASY 202150089.

show abstract

Dissecting the Underlying Pharmaceutical Mechanism of Chinese Traditional Medicine Yun-Pi-Yi-Shen-Tong-Du-Tang Acting on Ankylosing Spondylitis through Systems Biology Approaches

Cited by 7 publications

References 54 publications

Efficacy of Duhuo Jisheng Decoction in Treating Ankylosing Spondylitis: Clinical Evidence and Potential Mechanisms

Efficacy of Duhuo Jisheng Decoction in Treating Ankylosing Spondylitis: Clinical Evidence and Potential Mechanisms

Network Pharmacology and Molecular Docking Analysis Explores the Mechanisms of Cordyceps sinensis in the Treatment of Oral Lichen Planus

Effectiveness and safety of Chinese herbal formula combined with western medicine for ankylosing spondylitis

Contact Info

Product

Resources

About